Background and Aims: Several studies have indicated that cisplatin (cis-diamminedichloroplatinum II; CDDP) causes urinary excretion of L-carnitine (LC). However, the underlying cofactors affecting the increased urinary excretion remain unclear. The present study was performed to evaluate the dynamics of LC in plasma and urine after CDDP chemotherapy and to examine the relations with clinical parameters, such as gender, body mass index (BMI), and renal function. Methods: Twenty-two patients treated with CDDP therapy were selected. Blood and urine samples were taken from patients before starting CDDP treatment (day 0), on the next day (day 1), and on the seventh day (day 7). We measured plasma and urine concentrations of total, free, and acyl-LC, and examined the relationships with gender, age, treatment cycle, skeletal muscle mass, BMI, glomerular filtration rate, and change in creatinine concentration after CDDP administration. Results: Both urinary and plasma concentrations of 3 types of LC increased markedly on day 1 and subsequently reverted to the pre-CDDP level on day 7. There was a positive correlation between the % changes in plasma and urine LC (correlation coefficient 0.59, p = 0.003) on day 1, but no significant relations were seen in other clinical parameters. Conclusions: CDDP transiently increased plasma LC levels. The mechanism seemed to involve recruitment for marked urinary loss of LC. However, these changes in plasma and urinary LC levels were not related to clinical factors, suggesting that the dynamics of LC were independent of preexisting physical parameters.

1.
Rebouche CJ: Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism 1991;40:1305-1310.
2.
Peluso G, Nicolai R, Reda E, Benatti P, Barbarisi A, Calvani M: Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol 2000;182:339-350.
3.
Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol 2001;59:358-366.
4.
Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K: Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol 2009;31:664-669.
5.
Endo K, Tsuji A, Kondo S, Wakisaka N, Murono S, Yoshizaki T: Carnitine is associated with fatigue following chemoradiotherapy for head and neck cancer. Acta Otolaryngol 2015;135:846-852.
6.
Heuberger W, Berardi S, Jacky E, Pey P, Krahenbuhl S: Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 1998;54:503-508.
7.
Lancaster CS, Hu C, Franke RM, Filipski KK, Orwick SJ, Chen Z, Zuo Z, Loos WJ, Sparreboom A: Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res 2010;16:4789-4799.
8.
Hooke MC, McCarthy K, Taylor O, Hockenberry MJ: Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. Eur J Oncol Nurs 2015;19:7-12.
9.
Takahashi M, Ueda S, Misaki H, Sugiyama N, Matsumoto K, Matsuo N, Murao S: Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin Chem 1994;40:817-821.
10.
Kanda Y: Free statistical software: EZR (Easy R) on R commander. http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html (accessed August 1, 2012).
11.
Malaguarnera M, Risino C, Gargante MP, Oreste G, Barone G, Tomasello AV, Costanzo M, Cannizzaro MA: Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroenterol 2006;12:4541-4545.
12.
Kraft M, Kraft K, Gärtner S, Mayerle J, Simon P, Weber E, Schütte K, Stieler J, Koula-Jenik H, Holzhauer P, Gröber U, Engel G, Müller C, Feng YS, Aghdassi A, Nitsche C, Malfertheiner P, Patrzyk M, Kohlmann T, Lerch MM: L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial. Nutr J 2012;11:52.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.